中国组织工程研究 ›› 2022, Vol. 26 ›› Issue (8): 1286-1292.doi: 10.12307/2022.237
• 组织构建综述 tissue construction review • 上一篇 下一篇
阚厚铭1,范利君1,陈学泰1,申 文2
收稿日期:
2021-03-08
修回日期:
2021-03-09
接受日期:
2021-04-24
出版日期:
2022-03-18
发布日期:
2021-11-02
通讯作者:
申文,硕士,教授,主任医师,徐州医科大学附属医院疼痛科,江苏省徐州市 221002
作者简介:
阚厚铭,男,1991年生,安徽省砀山县人,汉族,徐州医科大学在读硕士,医师,主要从事慢性疼痛机制及临床研究。
范利君,女,1987年生,江苏省泗阳县人,汉族,徐州医科大学在读硕士,主治医师,主要从事骨癌痛分子机制研究。
基金资助:
Kan Houming1, Fan Lijun1, Chen Xuetai1, Shen Wen2
Received:
2021-03-08
Revised:
2021-03-09
Accepted:
2021-04-24
Online:
2022-03-18
Published:
2021-11-02
Contact:
Shen Wen, Master, Professor, Chief physician, Department of Pain Management, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China
About author:
Kan Houming, Master candidate, Physician, Jiangsu Provincial Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
Fan Lijun, Master candidate, Attending physician, Jiangsu Provincial Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
Supported by:
摘要:
文题释义:
富血小板血浆:是通过离心自体血液获取的具有高纯度血小板的血浆制品,已经广泛应用于骨关节外科、脊柱外科、皮肤科、康复科、疼痛科等科室,并在组织工程修复领域发挥重要作用。
神经病理性疼痛:是由于躯体感觉神经系统损伤或疾病所导致的感觉功能异常、痛觉敏感和自发性疼痛,分为中枢神经病理性疼痛和周围神经病理性疼痛,多在损伤因素消除后仍可伴有相应神经支配区的疼痛。
背景:神经病理性疼痛目前尚无特效治疗方案,患者长期忍受慢性疼痛困扰,严重影响生活质量。富血小板血浆通过释放多种生物活性因子,具有神经修复和缓解疼痛的作用,在神经病理性疼痛应用中具有巨大潜力。
目的:探讨富血小板血浆治疗神经病理性疼痛的原理,阐述富血小板血浆在不同类别神经病理性疼痛中的应用效果,以期为临床治疗提供新的思路与方法。
方法:中文以“富血小板血浆,神经病理性疼痛,神经损伤,神经痛”为检索词,在维普、中国知网、万方数据库检索相关文献;英文以“platelet rich plasma,neuropathic pain,nerve injury,neuralgia”为检索词,在Web of Science和PubMed 数据库检索相关文献;检索时间为1954年至2021年2月。根据纳入和排除标准,共选取107篇文献进行综述。
结果与结论:①富血小板血浆具有促进愈合和抗炎特性,既能修复受损神经组织,还能有效缓解疼痛,是治疗神经病理性疼痛的重要治疗手段,具有光明的前景;②富血小板血浆的制备方法仍存在争议,呼吁建立规范的制备方法和统一的成分评价标准;③富血小板血浆在脊髓损伤、周围神经损伤、神经卡压所致的神经病理性疼痛中的研究较多,在其他类别神经病理性疼痛中的作用机制和临床疗效尚需进一步研究。
https://orcid.org/0000-0001-5792-2901 (阚厚铭)
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程
中图分类号:
阚厚铭, 范利君, 陈学泰, 申 文. 富血小板血浆在神经病理性疼痛中的应用[J]. 中国组织工程研究, 2022, 26(8): 1286-1292.
Kan Houming, Fan Lijun, Chen Xuetai, Shen Wen. Application of platelet-rich plasma in neuropathic pain[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(8): 1286-1292.
[1] SCHOLZ J, FINNERUP NB, ATTAL N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1): 53-59. [2] KUFFLER DP. Mechanisms for Reducing Neuropathic Pain. Mol Neurobiol. 2020;57(1):67-87. [3] BOUHASSIRA D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175(1-2):16-25. [4] FINNERUP NB, SINDRUP SH, JENSEN TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3): 573-581. [5] LOVAGLIO AC, SOCOLOVSKY M, DI MASI G, et al. Treatment of neuropathic pain after peripheral nerve and brachial plexus traumatic injury. Neurol India. 2019;67(Supplement):S32-S37. [6] 朱谦, 樊碧发, 张达颖, 等. 周围神经病理性疼痛诊疗中国专家共识[J]. 中国疼痛医学杂志,2020,26(5):321-328. [7] KINGSLEY CS. Blood coagulation; evidence of an antagonist to factor VI in platelet-rich human plasma. Nature. 1954;173(4407):723-724. [8] CHAMATA ES, BARTLETT EL, WEIR D, et al. Platelet-Rich Plasma: Evolving Role in Plastic Surgery. Plast Reconstr Surg, 2021;147(1):219-230. [9] JUSTICZ N, DERAKHSHAN A, CHEN JX, et al. Platelet-Rich Plasma for Hair Restoration. Facial Plast Surg Clin North Am, 2020;28(2):181-187. [10] TANG R, WANG S, YANG J, et al. Application of platelet-rich plasma in traumatic bone infections. Expert Rev Anti Infect Ther. 2020:1-9. [11] SHAO S, PAN R, CHEN Y. Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer. Trends Endocrinol Metab. 2020;31(12):885-890. [12] EVERTS P, ONISHI K, JAYARAM P, et al. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci. 2020;21(20):7794-7830. [13] ORGANIZATION WHO. WHO releases new International Classification of Diseases (ICD 11).https://www.who.int/news-room/detail/18-06-2018-who-releases-new-international-classification-ofdiseases-(icd-11). [14] 吕岩, 程建国, 樊碧发, 等. ICD-11慢性疼痛分类中文编译版[J]. 中国疼痛医学杂志,2018,24(11):801-805. [15] 陈军, 王江林. 国际疼痛学会对世界卫生组织ICD-11慢性疼痛分类的修订与系统化分类[J]. 中国疼痛医学杂志,2019,25(5):323-330. [16] WHITE FA, JUNG H, MILLER RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA. 2007;104(51):20151-20158. [17] MCLACHLAN EM, JANIG W, DEVOR M, et al. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature. 1993;363(6429):543-546. [18] WOOLF CJ, SHORTLAND P, COGGESHALL RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992; 355(6355):75-78. [19] WOOLF CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983;306(5944):686-688. [20] FINNERUP NB, KUNER R, JENSEN TS. Neuropathic Pain: From Mechanisms to Treatment. Physiol Rev. 2021;101(1):259-301. [21] SEVCIK MA, GHILARDI JR, PETERS CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115(1-2): 128-141. [22] JI RR, BERTA T, NEDERGAARD M. Glia and pain: is chronic pain a gliopathy? Pain. 2013;154 (1):S10-S28. [23] MARX RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-228. [24] DOHAN ED, RASMUSSON L, ALBREKTSSON T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3): 158-167. [25] KIEB M, SANDER F, PRINZ C, et al. Platelet-Rich Plasma Powder: A New Preparation Method for the Standardization of Growth Factor Concentrations. Am J Sports Med. 2017;45(4):954-960. [26] CASTILLO TN, POULIOT MA, KIM HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011;39(2):266-271. [27] 卫愉轩, 张昭远, 范峥莹, 等. 中国富血小板血浆临床制备方法的研究进展[J]. 中华关节外科杂志(电子版),2020,14(2):196-200. [28] SLICHTER SJ, HARKER LA. Preparation and storage of platelet concentrates. Transfusion. 1976;16(1):8-12. [29] TAMIMI FM, MONTALVO S, TRESGUERRES I, et al. A comparative study of 2 methods for obtaining platelet-rich plasma. J Oral Maxillofac Surg. 2007;65(6):1084-1093. [30] CHAHLA J, CINQUE ME, PIUZZI NS, et al. A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. J Bone Joint Surg Am. 2017;99(20):1769-1779. [31] DO AR, DA SN, HADDAD NF, et al. Platelet-Rich Plasma Obtained with Different Anticoagulants and Their Effect on Platelet Numbers and Mesenchymal Stromal Cells Behavior In Vitro. Stem Cells Int. 2016; 2016(3):1-11. [32] KRAUS M, NEEB H, STRASSER E. ACD vs. sodium-citrate as an anticoagulant for platelet rich plasma (PRP) preparation influencestheextent of platelet shape change during spreading-quantitative morphometric data from standardized robotic darkfield microscopy. Hamostaseologie. 2018;38:A66-A67. [33] DU L, MIAO Y, LI X, et al. A Novel and Convenient Method for the Preparation and Activation of PRP without Any Additives: Temperature Controlled PRP. Biomed Res Int. 2018;2018:1761865. [34] NLÜ A, YILMAZ S, EKER B, et al. A Cycle of Freezing and Thawing as a Modified Method for Activating Platelets in Platelet-rich Plasma to Use in Regenerative Medicine. Panam J Trauma Crit Care Emerg Surg. 2020;9(2):101-104. [35] TUNALI M, OZDEMIR H, KUCUKODACI Z, et al. A novel platelet concentrate: titanium-prepared platelet-rich fibrin. Biomed Res Int. 2014;2014:209548. [36] Bordon Y. Innate immunity: Platelets on the prowl. Nat Rev Immunol. 2018;18(1):3. [37] PARK HB, YANG JH, CHUNG KH. Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: Upregulation of matrix metalloproteinase-1 and -9 in HaCaT cells. Korean J Hematol. 2011;46(4):265-273. [38] MITANI N, YUJIRI T, TANAKA Y, et al. Hematopoietic progenitor cell count, but not immature platelet fraction value, predicts successful harvest of autologous peripheral blood stem cells. J Clin Apher. 2011;26(3):105-110. [39] KUFFLER DP. Platelet-rich plasma and the elimination of neuropathic pain. Mol Neurobiol. 2013;48(2):315-332. [40] MEACHAM K, SHEPHERD A, MOHAPATRA DP, et al. Neuropathic Pain: Central vs. Peripheral Mechanisms. Curr Pain Headache Rep. 2017; 21(6):28. [41] ELLIS A, BENNETT DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111(1):26-37. [42] HERTER JM, ROSSAINT J, ZARBOCK A. Platelets in inflammation and immunity. J Thromb Haemost. 2015;12(11):1764-1775. [43] EL-SHARKAWY H, KANTARCI A, DEADY J, et al. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol. 2007;78(4):661-669. [44] HAGIHARA M, HIGUCHI A, TAMURA N, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol. 2004;172(9):5297-5303. [45] PARK JS, LEE EJ, LEE JC, et al. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways. Int Immunopharmacol. 2007;7(1):70-77. [46] SANCHEZ M, ANITUA E, DELGADO D, et al. Platelet-rich plasma, a source of autologous growth factors and biomimetic scaffold for peripheral nerve regeneration. Expert Opin Biol Ther. 2017;17(2):197-212. [47] MERIGHI A. Targeting the glial-derived neurotrophic factor and related molecules for controlling normal and pathologic pain. Expert Opin Ther Targets. 2016;20(2):193-208. [48] AL-MASSRI KF, AHMED LA, EL-ABHAR HS. Mesenchymal stem cells therapy enhances the efficacy of pregabalin and prevents its motor impairment in paclitaxel-induced neuropathy in rats: Role of Notch1 receptor and JAK/STAT signaling pathway. Behav Brain Res. 2019;360: 303-311. [49] ZHENG C, ZHU Q, LIU X, et al. Effect of platelet-rich plasma (PRP) concentration on proliferation, neurotrophic function and migration of Schwann cells in vitro. J Tissue Eng Regen Med. 2016;10(5):428-436. [50] LAI F, KAKUDO N, MORIMOTO N, et al. Platelet-rich plasma enhances the proliferation of human adipose stem cells through multiple signaling pathways. Stem Cell Res Ther. 2018;9(1):107. [51] ZOR F, DEVECI M, KILIC A, et al. Effect of VEGF gene therapy and hyaluronic acid film sheath on peripheral nerve regeneration. Microsurgery. 2014;34(3):209-216. [52] MAMMOTO T, JIANG A, JIANG E, et al. Platelet rich plasma extract promotes angiogenesis through the angiopoietin1-Tie2 pathway. Microvasc Res. 2013;89:15-24. [53] CASTRO MV, SILVA M, CHIAROTTO GB, et al. Reflex arc recovery after spinal cord dorsal root repair with platelet rich plasma (PRP). Brain Res Bull. 2019;152:212-224. [54] NEWTON K, DIXIT VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4(3):829-841. [55] COGNASSE F, LARADI S, BERTHELOT P, et al. Platelet Inflammatory Response to Stress. Front Immunol. 2019;10:1478. [56] GROS A, SYVANNARATH V, LAMRANI L, et al. Single platelets seal neutrophil-induced vascular breaches via GPVI during immune-complex-mediated inflammation in mice. Blood. 2015;126(8):1017-1026. [57] GILS JMV, ZWAGINGA JJ, HORDIJK PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol. 2008;85(2): 195-204. [58] ACOSTA-RODRIGUEZ EV, NAPOLITANI G, LANZAVECCHIA A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8(9):942-949. [59] HENN V, SLUPSKY JR, GRAFE M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391(6667):591-594. [60] WANG S, YANG J, ZHAO G, et al. Current applications of platelet gels in wound healing-A review. Wound Repair Regen. 2021;18(1):27-34. [61] ODEM MA, BAVENCOFFE AG, CASSIDY RM, et al. Isolated nociceptors reveal multiple specializations for generating irregular ongoing activity associated with ongoing pain. Pain. 2018;159(11):2347-2362. [62] NICHOLSON R, SMALL J, DIXON AK, et al. Serotonin receptor mRNA expression in rat dorsal root ganglion neurons. Neurosci Lett. 2003; 337(3):119-122. [63] KAMP J, VAN VELZEN M, OLOFSEN E, et al. Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Expert Opin Drug Metab Toxicol. 2019; 15(12):1033-1041. [64] AIYER R, MEHTA N, GUNGOR S, et al. A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice. Clin J Pain. 2018;34(5):450-467. [65] WONG HH, RANNIO S, JONES V, et al. NMDA receptors in axons: there’s no coincidence. J Physiol. 2021;599(2):367-387. [66] GUO W, CHU YX, IMAI S, et al. Further observations on the behavioral and neural effects of bone marrow stromal cells in rodent pain models. Mol Pain. 2016;12:1744806916658043. [67] FRANCONI F, MICELI M, ALBERTI L, et al. Further insights into the anti-aggregating activity of NMDA in human platelets. Br J Pharmacol. 1998; 124(1):35-40. [68] TSUDA M. Modulation of Pain and Itch by Spinal Glia. Neurosci Bull. 2018;34(1):178-185. [69] YANG PP, CHUEH SH, SHIE HL, et al. Effects of Hericium erinaceus Mycelium Extracts on the Functional Activity of Purinoceptors and Neuropathic Pain in Mice with L5 Spinal Nerve Ligation. Evid Based Complement Alternat Med. 2020;2020(3):1-12. [70] COHEN SP, MAO J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014;348:f7656. [71] MIKA J, ZYCHOWSKA M, POPIOLEK-BARCZYK K, et al. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013;716(1-3): 106-119. [72] BORHANI-HAGHIGHI M, MOHAMADI Y. The therapeutic effect of platelet-rich plasma on the experimental autoimmune encephalomyelitis mice. J Neuroimmunol. 2019;333:476958. [73] GIUSTI I, D’ASCENZO S, MACCHIARELLI G, et al. In vitro evidence supporting applications of platelet derivatives in regenerative medicine. Blood Transfus, 2020;18(2):117-129. [74] SIDDALL PJ, MCCLELLAND JM, RUTKOWSKI SB, et al. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain. 2003;103(3):249-257. [75] MICHETTI F, D’AMBROSI N, TOESCA A, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem. 2019;148(2): 168-187. [76] SAYO A, KONISHI H, KOBAYASHI M, et al. GPR34 in spinal microglia exacerbates neuropathic pain in mice. J Neuroinflammation. 2019; 16(1):82. [77] WANG A, XU C. The role of connexin43 in neuropathic pain induced by spinal cord injury. Acta Biochim Biophys Sin (Shanghai). 2019;51(6): 555-561. [78] UTTAM S, WONG C, AMORIM IS, et al. Translational profiling of dorsal root ganglia and spinal cord in a mouse model of neuropathic pain. Neurobiol Pain. 2018;4:35-44. [79] MIRANPURI GS, NGUYEN J, MORENO N, et al. Folic Acid Modulates Matrix Metalloproteinase-9 Expression Following Spinal Cord Injury. Ann Neurosci. 2019;26(2):60-65. [80] GWAK YS, HULSEBOSCH CE, LEEM JW. Neuronal-Glial Interactions Maintain Chronic Neuropathic Pain after Spinal Cord Injury. Neural Plast. 2017;2017:2480689. [81] SHEHADI JA, ELZEIN SM, BEERY P, et al. Combined administration of platelet rich plasma and autologous bone marrow aspirate concentrate for spinal cord injury: a descriptive case series. Neural Regen Res. 2021; 16(2):362-366. [82] SALARINIA R, HOSSEINI M, MOHAMADI Y, et al. Combined use of platelet-rich plasma and adipose tissue-derived mesenchymal stem cells shows a synergistic effect in experimental spinal cord injury. J Chem Neuroanat. 2020;110:101870. [83] CHEN NF, SUNG CS, WEN ZH, et al. Therapeutic Effect of Platelet-Rich Plasma in Rat Spinal Cord Injuries. Front Neurosci. 2018;12:252-264. [84] SALARINIA R, SADEGHNIA HR, ALAMDARI DH, et al. Platelet rich plasma: Effective treatment for repairing of spinal cord injury in rat. Acta Orthop Traumatol Turc. 2017;51(3):254-257. [85] DE CASTRO MV, DA SM, CHIAROTTO GB, et al. Spinal Reflex Recovery after Dorsal Rhizotomy and Repair with Platelet-Rich Plasma (PRP) Gel Combined with Bioengineered Human Embryonic Stem Cells (hESCs). Stem Cells Int. 2020;2020:8834360. [86] 冯振奋, 周宾宾, 魏卫兵, 等. 脊髓损伤后疼痛治疗的研究进展[J]. 中国康复理论与实践,2019,25(6):652-656. [87] GRIFFIN JW, HOGAN MV, CHHABRA AB, et al. Peripheral nerve repair and reconstruction. J Bone Joint Surg Am. 2013;95(23):2144-2151. [88] LI L, CAI J, YUAN Y, et al. Platelet-rich plasma can release nutrient factors to promote facial nerve crush injury recovery in rats. Saudi Med J. 2019;40(12):1209-1217. [89] 朱亚琼, 金壮, 汪靖, 等. 超声引导注射富血小板血浆修复坐骨神经挤压伤[J]. 中国组织工程研究,2020,24(20):3196-3201. [90] ZHU Y, JIN Z, FANG J, et al. Platelet-Rich Plasma Combined with Low-Dose Ultrashort Wave Therapy Accelerates Peripheral Nerve Regeneration. Tissue Eng Part A. 2020;26(3-4):178-192. [91] IKUMI A, HARA Y, OKANO E, et al. Intraoperative Local Administration of Platelet-Rich Plasma (PRP) during Neurolysis Surgery for the Treatment of Digital Nerve Crush Injury. Case Rep Orthop. 2018;2018:1275713. [92] 王兴平.富血小板血浆在后路颈椎减压后C5神经麻痹治疗中的价值[J].中国组织工程研究,2016,20(46):6930-6936. [93] HUANG SH, WU SH, LEE SS, et al. Platelet-Rich Plasma Injection in Burn Scar Areas Alleviates Neuropathic Scar Pain. Int J Med Sci. 2018;15(3): 238-247. [94] 中华医学会疼痛学分会. 脊柱退变性神经根疼痛治疗专家共识[J]. 中华医学杂志,2019,99(15):1133-1137. [95] BHATIA R, CHOPRA G. Efficacy of Platelet Rich Plasma via Lumbar Epidural Route in Chronic Prolapsed Intervertebral Disc Patients-A Pilot Study. J Clin Diagn Res. 2016;10(9):C5-C7. [96] BISE S, DALLAUDIERE B, PESQUER L, et al. Comparison of interlaminar CT-guided epidural platelet-rich plasma versus steroid injection in patients with lumbar radicular pain. Eur Radiol. 2020;30(6):3152-3160. [97] RUIZ-LOPEZ R, TSAI YC. A Randomized Double-Blind Controlled Pilot Study Comparing Leucocyte-Rich Platelet-Rich Plasma and Corticosteroid in Caudal Epidural Injection for Complex Chronic Degenerative Spinal Pain. Pain Pract. 2020;20(6):639-646. [98] LAM K, HUNG CY, WU TJ. Ultrasound-Guided Cervical Intradiscal Injection with Platelet-Rich Plasma with Fluoroscopic Validation for the Treatment of Cervical Discogenic Pain: A Case Presentation and Technical Illustration. J Pain Res. 2020;13:2125-2129. [99] SHIRI R, MIRANDA H, HELIOVAARA M, et al. Physical work load factors and carpal tunnel syndrome: a population-based study. Occup Environ Med. 2009;66(6):368-373. [100] SENNA MK, SHAAT RM, ALI A. Platelet-rich plasma in treatment of patients with idiopathic carpal tunnel syndrome. Clin Rheumatol. 2019; 38(12):3643-3654. [101] WU YT, HO TY, CHOU YC, et al. Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: A prospective randomized, single-blind controlled trial. Sci Rep. 2017;7(1):94. [102] RAEISSADAT SA, KARIMZADEH A, HASHEMI M, et al. Safety and efficacy of platelet-rich plasma in treatment of carpal tunnel syndrome; a randomized controlled trial. BMC Musculoskelet Disord. 2018;19(1): 49. [103] HASSANIEN M, ELAWAMY A, KAMEL EZ, et al. Perineural Platelet-Rich Plasma for Diabetic Neuropathic Pain, Could It Make a Difference? Pain Med. 2020;21(4):757-765. [104] ANJAYANI S, WIROHADIDJOJO YW, ADAM AM, et al. Sensory improvement of leprosy peripheral neuropathy in patients treated with perineural injection of platelet-rich plasma. Int J Dermatol. 2014;53(1): 109-113. [105] RAVINDRAN S, CRITON S. Sensory improvement of leprosy peripheral neuropathy in patients treated with perineural injection of platelet-rich plasma. Int J Dermatol. 2018;57(4):491-492. [106] 黄立荣, 郭佳妮, 张慧芝, 等. MRI导航下背根神经节脉冲射频联合富血小板血浆治疗带状疱疹后神经痛[J]. 中国疼痛医学杂志, 2020,26(6):459-462. [107] DE ANGELIS B, LUCARINI L, ORLANDI F, et al. Regenerative surgery of the complications with Morton’s neuroma surgery: use of platelet rich plasma and hyaluronic acid. Int Wound J. 2013;10(4):372-376. |
[1] | 吴 亮, 王 强, 王文博, 辛天闻, 郗 焜, 唐锦程, 徐敬之, 陈 亮, 顾 勇. 脊髓型颈椎病发生创伤性颈髓中央综合征的危险因素分析[J]. 中国组织工程研究, 2022, 26(9): 1388-1394. |
[2] | 胡 伟, 谢兴奇, 屠冠军. 骨髓间充质干细胞来源外泌体改善脊髓损伤后血脊髓屏障的完整性[J]. 中国组织工程研究, 2022, 26(7): 992-998. |
[3] | 安维政, 何 萧, 任 帅, 刘建宇. 肌源干细胞在周围神经再生中的潜力[J]. 中国组织工程研究, 2022, 26(7): 1130-1136. |
[4] | 范一鸣, 刘方煜, 张洪宇, 李 帅, 王岩松. 脊髓损伤后室管膜区内源性神经干细胞反应的系列问题[J]. 中国组织工程研究, 2022, 26(7): 1137-1142. |
[5] | 刘 超, 张丽君, 杜心洁, 许 茜, 吕红娟, 范冬梅, 田焕玲, 黄 健, 黄玉香. 人脐带间充质干细胞促进血小板血浆凝固的机制[J]. 中国组织工程研究, 2022, 26(25): 4010-4015. |
[6] | 王 康, 智晓东, 王 伟. 人羊膜上皮细胞修复损伤神经的作用及机制[J]. 中国组织工程研究, 2022, 26(25): 4046-4051. |
[7] | 石 尧, 韩树峰, 原一桐, 杜若琛, 景志杰, 赵碧春, 张茹鑫, 张玉娟, 王春芳. 人脐带间充质干细胞治疗脊髓损伤有效性与安全性的Meta分析[J]. 中国组织工程研究, 2022, 26(25): 4093-4100. |
[8] | 陈平波, 王 晶, 孙 勇, 徐晓峰, 陈 谦, 张志坚. 京尼平交联音猬因子复合纤维蛋白支架修复大鼠脊髓损伤[J]. 中国组织工程研究, 2022, 26(21): 3345-3350. |
[9] | 严崎方, 谢翠柳, 鄢国伟. 浓缩生长因子与生物陶瓷材料iRoot BP 体外对人牙髓细胞存活、 增殖和矿化的影响[J]. 中国组织工程研究, 2022, 26(21): 3363-3368. |
[10] | 李剑锋, 张淑莲, 闫金玉, 李佳艺, 金 朝, 邓 琦. siRNA沉默波形蛋白表达抑制大鼠急性脊髓损伤胶质瘢痕的形成[J]. 中国组织工程研究, 2022, 26(20): 3190-3195. |
[11] | 孙新政, 陈晓可, 王成浩, 何 辉. 运动改善动物坐骨神经损伤性疼痛的Meta分析[J]. 中国组织工程研究, 2022, 26(2): 321-328. |
[12] | 周俊丽, 王小俊, 王海焦, 李 春. 新型医用敷料治疗糖尿病足溃疡疗效比较的网状Meta分析[J]. 中国组织工程研究, 2022, 26(16): 2562-2569. |
[13] | 柴 乐, 丁 晓, 王 斌, 陈 旭, 郭甲瑞, 朱光普, 余进伟. 富血小板血浆联合生物陶瓷系统治疗ARCO Ⅱ期股骨头坏死[J]. 中国组织工程研究, 2022, 26(15): 2347-2351. |
[14] | 李世杰, 马立琼, 熊贤梅, 张 严, 陈梓杰, 冯俊铭, 高怡加, 曾展鹏. 三七总皂苷对富血小板血浆促进兔骨缺损愈合的影响[J]. 中国组织工程研究, 2022, 26(14): 2155-2160. |
[15] | 李传鸿, 俞 兴, 杨永栋, 赵 赫. 脊髓损伤中的小胶质细胞:M1/M2表型极化发挥神经毒性/神经保护作用[J]. 中国组织工程研究, 2022, 26(14): 2265-2272. |
文题释义:#br# 富血小板血浆:是通过离心自体血液获取的具有高纯度血小板的血浆制品,已经广泛应用于骨关节外科、脊柱外科、皮肤科、康复科、疼痛科等科室,并在组织工程修复领域发挥重要作用。#br# 神经病理性疼痛:是由于躯体感觉神经系统损伤或疾病所导致的感觉功能异常、痛觉敏感和自发性疼痛,分为中枢神经病理性疼痛和周围神经病理性疼痛,多在损伤因素消除后仍可伴有相应神经支配区的疼痛。#br# 中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程
神经病理性疼痛是由于躯体感觉神经系统损伤或疾病所导致的感觉功能异常、痛觉敏感和自发性疼痛。多数在损伤因素消除后仍可伴有相应神经支配区的疼痛,表现为自发性痛、痛觉超敏、痛觉过敏、感觉异常。目前减轻神经病理性疼痛的治疗药物包括三环类抗抑郁药、5-羟色胺去甲肾上腺素再摄取抑制剂、抗惊厥药加巴喷丁和普瑞巴林,以及阿片类药物。然而,药物治疗效果往往有限,需要配合物理治疗、神经调控、手术干预等多模式治疗方案。慢性疼痛及功能受限导致患者社会参与减少,对患者造成严重的心理、经济负担。
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||